Orgenesis Inc

Orgenesis Inc Stock Forecast & Price Prediction

Live Orgenesis Inc Stock (ORGS) Price
$0.61

1

Ratings

  • Buy 1
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$0.61

P/E Ratio

-0.36

Volume Traded Today

$67,400

Dividend

Dividends not available for ORGS

52 Week High/low

1.08/0.25

Orgenesis Inc Market Cap

$34.2M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $ORGS ๐Ÿ›‘

Before you buy ORGS you'll want to see this list of ten stocks that have huge potential. Want to see if ORGS made the cut? Enter your email below

ORGS Summary

The Orgenesis Inc (ORGS) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered ORGS. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for ORGS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

ORGS Analyst Ratings

Orgenesis Inc has a total of 1 Wall St Analyst ratings. There are 1 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Orgenesis Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

ORGS stock forecast by analyst

These are the latest 20 analyst ratings of ORGS.

Analyst/Firm

Rating

Price Target

Change

Date

Kenneth Bruce
Benchmark

Speculative Buy

$6

Reiterates

Jun 14, 2023
Kenneth Bruce
Benchmark

Buy

$6

Reiterates

Mar 22, 2023

Benchmark

Speculative Buy

$9

Initiates

Sep 26, 2019

ORGS Company Information

  • Company Name: Orgenesis Inc.
  • Industry: Biotech, focusing on cell and gene therapies worldwide.
  • Business Model: Operates through two segments - Octomera and Therapies.
  • Key Technology: Develops a Point of Care (POCare) platform for cell-based therapies.
  • Therapy Types: Includes autologous cell-based immunotherapies and treatments for:
    • Metabolic diseases
    • Anti-viral diseases
    • Tissue regeneration
  • Development Services: Offers regulatory services, pre-clinical studies, intellectual property services, and GMP process translation.
  • Support Services: Provides hospital services, cell process development, and distributed cell processing services.
  • History: Formerly known as Business Outsourcing Service, Inc.; rebranded to Orgenesis Inc. in August 2011.
  • Incorporation: Established in 2008 and headquartered in Germantown, Maryland.
ORGS
Orgenesis Inc (ORGS)

When did it IPO

N/A

Staff Count

146

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Ms. Vered Caplan M.Sc.

Market Cap

$34.2M

Orgenesis Inc (ORGS) Financial Data

In 2023, ORGS generated $530,000 in revenue, which was a decrease of -98.53% from the previous year. This can be seen as a signal that ORGS's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$7.7M

Revenue From 2021

$35.5M

363.96 %
From Previous Year

Revenue From 2022

$36.0M

1.47 %
From Previous Year

Revenue From 2023

$530,000

-98.53 %
From Previous Year
  • Revenue TTM $662,000
  • Operating Margin TTM -1,653.7%
  • Gross profit TTM $-5,725,000
  • Return on assets TTM -30.1%
  • Return on equity TTM -727.2%
  • Profit Margin -1,080.2%
  • Book Value Per Share -0.33%
  • Market capitalisation $34.2M
  • Revenue for 2021 $35.5M
  • Revenue for 2022 $36.0M
  • Revenue for 2023 $530,000
  • EPS this year (TTM) $-0.80

Orgenesis Inc (ORGS) Latest News

No news data available.

...

ORGS Frequently asked questions

The highest forecasted price for ORGS is $ from at .

The lowest forecasted price for ORGS is $ from from

The ORGS analyst ratings consensus are 1 buy ratings, 0 hold ratings, and 0 sell ratings.